

Bundled Pay for Care Coordination Proposed

BY ALICIA AULT

Associate Editor, Practice Trends

WASHINGTON — The U.S. health care delivery system should be overhauled to organize medical practice around “integrated care cycles” that are coordinated by a central physician and to reward physicians for providing value, Michael E. Porter said at a media briefing presented by the Journal of the American Medical Association.

The proposals are a shortened version of a book written by Mr. Porter, the Bishop William Lawrence University Professor at Harvard Business School, and his coauthor, Elizabeth Olmsted Teisberg of the University of Virginia’s Darden Graduate School of Business.

According to Mr. Porter and Ms. Teisberg, a value-based system has three principles: providing value for patients, organizing delivery of care around conditions and care cycles, and measuring results, preferably risk-adjusted outcomes that are measured over the full cycle of care, not just an individual care episode (JAMA 2007;297:1103-11).

“Physicians focused on value for patients will no longer see themselves as self-contained, isolated actors,” the authors wrote. “Instead, they will build stronger professional connections with complementary specialists who contribute to patient care across the care cycles for their patients.”

The authors pointed out that they do not advocate a single-payer system. They say instead that competition is healthy but the current system supports the wrong kind of competition.

It rewards physicians and health plans for taking patients away from one another or for shifting costs onto a competitor, rather than for providing value for the patient in the form of improved clinical outcomes, the authors said.

Their model is similar to the medical home concept that’s being promoted by the American College of Physicians and the American Academy of Family Physicians. Under the concept, physicians would provide a bundled payment to a physician to coordinate care and there would be a pay-for-performance element based on patient outcomes.

Medicare will pay for a 3-year, eight-state demonstration of the medical home, and ACP and AAFP are working with IBM on testing such a program with its employees in Austin, Tex.

Physicians are in the best position to change the delivery of health care, Mr. Porter and Ms. Teisberg said. They could

lead by becoming part of a care team and agreeing to accept a piece of a payment that would be bundled for the episode of care, not for an individual service. And they can take the lead in defining outcomes measurements, Mr. Porter said at the briefing.

In the article, the authors said that pay-for-performance models are also going down the wrong track, because they are aimed only at getting physicians to comply with processes of care. That will not

provide value to the patient and will likely lead to micromanagement of medical practice, they said.

A study published the same week in the New England Journal of Medicine found that pay-for-performance proposals under Medicare aren’t likely to work well under the current system, because patients’ care is not being coordinated by a single provider. In fact, beneficiaries are seeing multiple physicians—typically seven physicians in four practices in a given year—

which “impedes the ability of any one assigned provider to influence the overall quality of care for a given patient,” wrote the investigators, who were with the Center for Studying Health System Change and Memorial Sloan-Kettering Cancer Center (N. Engl. J. Med. 2007;356:1130-9).

Mr. Porter and Ms. Teisberg envision a future where care is delivered efficiently by physicians allied in partnerships or working for large group practices or staff-model managed care organizations. ■

DIOVAN HCT: Power to help get to BP goal



patients achieved JNC 7 goal

with DIOVAN HCT 320/25 mg in Stage 1 hypertension^{1,2}

JNC 7 goal: BP <140/90 mm Hg.

In this double-blind, placebo-controlled study, hypertensive patients (N=1,346) were randomized to one of eight treatment arms: HCTZ 12.5 mg once daily, HCTZ 25 mg once daily, valsartan 160 mg once daily, valsartan 320 mg once daily, DIOVAN HCT 160/12.5 mg once daily, DIOVAN HCT 320/12.5 mg once daily, DIOVAN HCT 320/25 mg once daily, or placebo. Patients randomized to DIOVAN HCT 320/12.5 mg once daily or DIOVAN HCT 320/25 mg once daily received DIOVAN HCT 160/12.5 mg once daily during the first week of treatment, and were then titrated to their respective final doses. Patients in the other treatment arms remained on their initial doses for the entire treatment period. Patients were treated for a total of 8 weeks. Results shown are from a subgroup analysis in patients with Stage 1 hypertension. Goal rates are at end point (8 weeks). Mean baseline BP was 146/97 mm Hg for the DIOVAN HCT 320/25-mg group (n=80) and 144/97 mm Hg for the placebo group (n=89).

Goal rate with placebo was 39%.

Important Considerations

USE IN PREGNANCY: When used in pregnancy, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, valsartan or DIOVAN HCT should be discontinued as soon as possible. See **WARNINGS** in brief summary of Prescribing Information on adjacent page.

Valsartan and DIOVAN HCT are contraindicated in patients who are hypersensitive to any component of these products. Because of the thiazide component, DIOVAN HCT is contraindicated in patients with anuria or hypersensitivity to sulfonamide-derived drugs.

Volume- and/or salt-depletion should be corrected in patients prior to administering valsartan or DIOVAN HCT or symptomatic hypotension may occur.

Care should be exercised with dosing of valsartan in patients with severe renal impairment. As a consequence of inhibiting the renin-angiotensin system, changes in renal function may be observed in susceptible individuals (eg, patients with renal artery stenosis or severe heart failure).

Important considerations due to the hydrochlorothiazide component: Thiazide diuretics should be used with caution in patients with impaired hepatic function or progressive liver disease. Lithium generally should not be given with thiazides. Thiazides have been reported to cause exacerbation or activation of systemic lupus erythematosus. Patients taking DIOVAN HCT should be observed for clinical signs of fluid or electrolyte imbalance.

In hypertension, the most common adverse events with valsartan and DIOVAN HCT: headache and dizziness.

Valsartan or DIOVAN HCT are indicated for the treatment of hypertension.

DIOVAN HCT is for patients who need even more than valsartan or HCTZ alone and is not indicated for initial therapy.

Diovan HCT[®]
valsartan/hydrochlorothiazide tablets

Powerful efficacy... Proven benefits

Internal Medicine News

is the best-read publication among
office- and hospital-based
internal medicine specialists.

Thanks For
Making Us #1

Source: Focus™, December 2006,
Office and Hospital Internists,
Projected Average Issue Readers, Tables 501 & 502